Medical cannabis sold by gLeaf is for use only by qualifying patients.
GLEAF's sales plummeted 67.1% YoY, reflecting a drastic shift in market dynamics. With a 3-month trend of -31.8%, the premium brand faces increasing competitive pressure. This decline raises concerns about its pricing strategy and market positioning.
Flower dominates GLEAF's portfolio at 75.3% but has dropped 67.7% YoY. Vapes hold 9.7% (-35.6% YoY), while Pre-Rolls show a staggering decline at -88.9%. Concentrates and Oral categories also struggle, indicating a challenging market.
Category
Sales Share
Avg Price
YoY
Flower
80.4%
$48.47
70.3%
Vapes
6.1%
$31.17
83.5%
Pre-Rolls
4.3%
$32.28
92.9%
Concentrates
3.6%
$30.94
70.1%
Oral
3.4%
$29.66
79.2%
Topicals
2.1%
$49.97
56.4%
Trend View
Market Insights SnapshotJun 2026
24-Month Trend
Average Price
$42.8
YoY Sales Trend
74.9%
2Y Sales Trend
87.6%
Category Breakout
Category
Sales Share
Avg Price
YoY
Flower
80.4%
$48.47
70.3%
Vapes
6.1%
$31.17
83.5%
Pre-Rolls
4.3%
$32.28
92.9%
Concentrates
3.6%
$30.94
70.1%
Oral
3.4%
State Rank Table
State
Flower
Vapes
Pre-Roll
Concentrates
Oral
Topicals
Virginia
10
13
10
⊖
⊖
⊖
Pennsylvania
⊖
⊖
⊖
35
9
5
GLEAF's strongest foothold is in Virginia (50.5%), followed by Pennsylvania (36.9%) and Maryland (12.6%). The brand operates across 3 states, highlighting a concentrated geographic presence among top cannabis brands.
Gleaf Top StatesJun 2026
